TriangleOdronextamab (NCT06784726)
Odronextamab trial for Recurrent Diffuse Large B-Cell Lymphoma (NCT06784726). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with selected large B-cell lymphomas after failed first-line treatment, including anti-CD20 therapy, who qualify for CAR T therapy.
The idea: intravenous odronextamab binds CD3 on T cells and CD20 on lymphoma cells. It is given before cell collection to test whether patients can reach CAR T treatment. Complete responders after two cycles may instead continue odronextamab. Others proceed through cell collection, lymphodepletion, and CAR T infusion when possible.
This phase 2 study plans 27 patients. Mengyang Di leads at Fred Hutch/UW in Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.